Sam Brusco, Associate Editor05.02.23
Zimmer Biomet began an agreement to acquire OSSIS, a privately-held company specializing in personalized 3D implants and complex hip replacements, including second-time hip replacements and those involving bone tumors and trauma.
OSSIS offers rapid personalized implant design and production that align with Zimmer Biomet’s push to provide personalized experiences. Zimmer Biomet began an agreement with OSSIS in July 2021 to become the company’s Asia-Pacific partner for patient-specific, 3D-printed titanium hip joint replacements and other pelvic bone replacement surgery.
The partnership was expanded to Europe, Middle East, and Africa in December 2022. This acquisition marks the continuation of the partnership and will let Zimmer Biomet boost OSSIS’ hip reconstruction portfolio.
"Combining OSSIS's more than 16 years of clinical experience and engineering expertise with Zimmer Biomet's extensive network across Asia Pacific, Europe, Middle East and Africa demonstrates our commitment to bring transformative med tech advancements to patients in need," Sang Yi, Zimmer Biomet Asia Pacific Group president, told the press. "We are very pleased to partner with these patients and their physicians as we work toward our mission to alleviate pain and improve the quality of life for people around the world."
"Zimmer Biomet shares our ethos of innovative technology with a strong patient focus, and OSSIS is thrilled to join Zimmer Biomet's established portfolio with cutting-edge solutions and expert capabilities," added Kelvin Hyland, OSSIS managing director.
Zimmer Biomet also acquired soft tissue healing firm Embody earlier this year.
OSSIS offers rapid personalized implant design and production that align with Zimmer Biomet’s push to provide personalized experiences. Zimmer Biomet began an agreement with OSSIS in July 2021 to become the company’s Asia-Pacific partner for patient-specific, 3D-printed titanium hip joint replacements and other pelvic bone replacement surgery.
The partnership was expanded to Europe, Middle East, and Africa in December 2022. This acquisition marks the continuation of the partnership and will let Zimmer Biomet boost OSSIS’ hip reconstruction portfolio.
"Combining OSSIS's more than 16 years of clinical experience and engineering expertise with Zimmer Biomet's extensive network across Asia Pacific, Europe, Middle East and Africa demonstrates our commitment to bring transformative med tech advancements to patients in need," Sang Yi, Zimmer Biomet Asia Pacific Group president, told the press. "We are very pleased to partner with these patients and their physicians as we work toward our mission to alleviate pain and improve the quality of life for people around the world."
"Zimmer Biomet shares our ethos of innovative technology with a strong patient focus, and OSSIS is thrilled to join Zimmer Biomet's established portfolio with cutting-edge solutions and expert capabilities," added Kelvin Hyland, OSSIS managing director.
Zimmer Biomet also acquired soft tissue healing firm Embody earlier this year.